HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elkins, C. C. Articles by Bender, H. W. Search for Related Content PubMed PubMed Citation Articles by Elkins, C. C. Articles by Bender, H. W., Jr

The Annals of Thoracic Surgery, Vol 56, 1267-1272, Copyright © 1993 by The Society of Thoracic Surgeons

ARTICLES

Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated?

CC Elkins, WH Frist, JS Dummer, JR Stewart, WH Merrill, KA Carden and HW Bender Jr
Department of Thoracic and Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee 37232-5734.

To determine the efficacy of acyclovir prophylaxis in preventing cytomegalovirus (CMV) disease after heart transplantation, the clinical course of 103 patients (ages, 0.1 to 62 years; mean age, 41.8 years; 87 males, 16 females) was analyzed. Active CMV infection (defined as a positive culture from any site or a fourfold increase in immunoglobulin G antibody titers) occurred in 64% (66/103) and clinical CMV disease (defined as pathologic evidence of CMV in tissue biopsy or a typical CMV syndrome with fever and two of the following: leukopenia, thrombocytopenia, atypical lymphocytes, and elevated liver function test results in a patient with CMV infection) occurred in 25% (26/103). Independent variables studied included acyclovir prophylaxis, duration of acyclovir use, duration and type of induction therapy, donor and recipient CMV status, total steroid dose at 3 and 6 months, azathioprine dose and cyclosporine level at 3 months, age, and sex. In a multivariate regression analysis, acyclovir prophylaxis was independently associated with freedom from CMV disease (p = 0.029). Positive donor CMV status (p = 0.025), higher total steroid dose at 3 months (p = 0.036), and lower azathioprine dose at 3 months (p = 0.047) were associated with higher occurrence of CMV disease. The use of antilymphocyte induction therapy was associated with an increased occurrence of active CMV infection (p = 0.022) but not CMV disease. The prophylactic administration of acyclovir reduced the occurrence of CMV disease after heart transplantation.

This article has been cited by other articles:

				C. L. Talarico, T. C. Burnette, W. H. Miller, S. L. Smith, M. G. Davis, S. C. Stanat, T. I. Ng, Z. He, D. M. Coen, B. Roizman, et al. Acyclovir Is Phosphorylated by the Human Cytomegalovirus UL97 Protein Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1941 - 1946. [Abstract] [Full Text]

				W. M. DeCampli, H. Luikart, S. Hunt, and E. B. Stinson Characteristics of patients surviving more than ten years aftercardiac transplantation J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1103 - 1115. [Abstract] [Full Text]